What Are Peptides?

The word is doing a lot of work

A peptide is a short chain of amino acids. That is the entire definition. Insulin is a peptide. So is the GLP-1 drug your neighbour is taking. So is the vial someone is selling on a forum with no approval anywhere in the world.

That range is the whole problem. When a supplement is marketed as peptide therapy, the word borrows the credibility of the approved drugs while describing something that may have never been tested in a person.

So this piece is not about whether peptides work. Some obviously do; they are medicines. It is about telling apart the two categories that the marketing deliberately blends.

The review that draws the line

One review states the split directly, which is why it leads here.

Researchers reviewed 106 articles, prioritising systematic reviews, meta-analyses and randomised controlled trials across PubMed, ScienceDirect and SciELO, covering the effects, clinical applications, safety profiles and regulatory status of prominent therapeutic peptides.

Prioritising the strongest study designs, and including regulatory status as an outcome alongside efficacy. That second choice is unusual and it is the useful one.

Their framing of the landscape is the sentence to carry: while several peptide drugs have undergone rigorous approval processes that evaluate both safety and efficacy, novel unapproved compounds have emerged and are rapidly expanding into preventive medicine and performance enhancement.

Two populations of compound, one word covering both. The approved ones went through the process. The ones expanding into performance enhancement did not.

On the approved side the review is positive: therapeutic peptides are described as a promising tool for treating type 2 diabetes and obesity, for skin rejuvenation, and as hormone analogs for specific conditions.

And it closes with the qualifier that applies to everything downstream of that: these are described as strategic and innovative options that can improve health, performance and longevity, with the authors stating that further study is required.

This is a narrative review covering a wide range of compounds and conditions, and it does not evaluate any single peptide to the depth a decision about taking one would require. Approved peptide medicines are prescription drugs, and the decision to use one belongs with a doctor.

BPC-157, and what its evidence actually is

If you have encountered peptides through fitness rather than medicine, you have encountered this one. Here is the state of it.

A review describes BPC-157 as a synthetic pentadecapeptide derived from gastric proteins that has demonstrated reparative and anti-inflammatory properties across diverse preclinical models. Experimental evidence shows it supports angiogenesis, collagen synthesis, fibroblast activity and modulation of nitric oxide pathways, contributing to enhanced healing of muscle, tendon, ligament, bone and gastrointestinal tissue, with reduced inflammatory cytokine activity and improved microvascular integrity reported.

That is a genuinely impressive list of effects. Now the word that governs all of it: preclinical.

The review is explicit about the human picture. Although animal data indicate favourable safety and pharmacokinetics, human research remains limited to small pilot studies in musculoskeletal pain, interstitial cystitis and intravenous administration, all suggesting potential therapeutic value without reported major adverse effects.

Small pilot studies. Three indications. That is the entire human evidence base for a compound sold widely as a healing agent.

And the authors name the practical problem on top of the evidence gap: inconsistent preparation standards and limited clinical validation.

Inconsistent preparation standards means that even if the molecule worked exactly as the animal data suggest, what is in an unregulated vial is not a known quantity. You would be dosing something whose identity and purity nobody has verified.

This is a review of preclinical evidence with a small human literature attached. It does not establish efficacy in people, and BPC-157 is not an approved medicine in major jurisdictions. Nothing here is a recommendation to use it, and I would not take it.

The one peptide most people already take

There is a peptide with a much less exciting reputation and a much more ordinary evidence base, and it is worth ending on.

Collagen peptides are studied alongside whey protein for effects on musculoskeletal tissue, and a study set out to test their combined efficacy in resistance training, on the reasoning that the two may act on bone and muscle in complementary ways.

Collagen peptides are a peptide product, sold in supermarkets, at doses in grams rather than micrograms, with no needle involved.

I raise it to make a point about the category rather than to recommend it. Nobody markets collagen with the mystique attached to a research-chemical vial, and yet it sits in the same chemical class. The glamour around peptides is not tracking the chemistry. It is tracking how hard something is to obtain.

When a compound is easy to buy and openly studied, it gets discussed soberly. When it is hard to obtain and thinly evidenced, it acquires a mythology. That inversion is worth noticing, because it is the opposite of how you should be weighing things.

That framing is my argument, not a finding of the study cited, which examined combined whey and collagen supplementation on bone mineral density and muscle mass in a resistance training context.

How I would think about this

Separate approved medicines from everything else, every time. GLP-1 drugs and insulin went through trials measuring both safety and efficacy. A compound expanding into performance enhancement without approval did not, and sharing a chemical class confers nothing.

Treat preclinical as a hypothesis. BPC-157's impressive profile is in animals, with human evidence limited to small pilot studies in three indications.

Take the manufacturing problem as seriously as the evidence problem. Inconsistent preparation standards means you cannot know what is in an unregulated vial regardless of what the molecule does.

Notice when mystique is inversely proportional to evidence. The peptide in the supermarket is studied openly. The one that is hard to get carries the mythology.

And do not inject anything on the strength of an article, including this one. Anything involving an injectable compound is a conversation with a doctor who knows your history, and several of these are prescription-only or unapproved for good reason.

These are my conclusions from the material rather than clinical recommendations. Nothing in this article is medical advice.